DFIVX
Price
$33.52
Change
+$0.34 (+1.02%)
Updated
Aug 21 closing price
Net Assets
15.02B
VIHAX
Price
$50.90
Change
+$0.55 (+1.09%)
Updated
Aug 21 closing price
Net Assets
21.87B
Interact to see
Advertisement

DFIVX vs VIHAX

DFIVX vs VIHAX Comparison Chart in %
View a ticker or compare two or three
VS
DFIVX vs. VIHAX commentary
Aug 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DFIVX is a Buy and VIHAX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
VIHAX has more cash in the bank: 21.9B vs. DFIVX (15B). DFIVX pays higher dividends than VIHAX: DFIVX (3.64) vs VIHAX (3.45). DFIVX was incepted earlier than VIHAX: DFIVX (33 years) vs VIHAX (10 years). DFIVX (0.48) is less costly to investors than VIHAX (0.16). DFIVX is a more actively managed with annual turnover of: 13.00 vs. VIHAX (9.00). DFIVX has a lower initial minimum investment than VIHAX: DFIVX (0) vs VIHAX (3000). DFIVX annual gain was more profitable for investors over the last year : 31.98 vs. VIHAX (25.96). DFIVX return over 5 years is better than : 110.78 vs. VIHAX (66.41).
DFIVXVIHAXDFIVX / VIHAX
Total Expense Ratio0.280.16175%
Annual Report Gross Expense Ratio0.480.16300%
Fund Existence33 years10 years-
Gain YTD18.78817.601107%
Front LoadN/AN/A-
Min. Initial Investment03000-
Min. Initial Investment IRAN/AN/A-
Net Assets15B21.9B68%
Annual Yield % from dividends3.643.45106%
Returns for 1 year31.9825.96123%
Returns for 3 years98.3075.63130%
Returns for 5 years110.7866.41167%
Returns for 10 years161.16108.07149%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RMOCX19.250.23
+1.21%
Victory RS Mid Cap Growth C
CIVHX22.290.17
+0.77%
American Funds Intl Vntg 529-F-3
GSYPX45.930.22
+0.48%
Goldman Sachs Small Cap Value P
PASTX68.290.18
+0.26%
T. Rowe Price Science & Tech Adv
JMNCX12.25-0.01
-0.08%
JPMorgan Research Market Neutral C